Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 254-265

  Takahashi, Takehiro ^a   Asano, Yoshihide ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Taniguchi, Takashi ^a   Noda, Shinji ^a   Akamata, Kaname ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; HYDROXYPROLINE; IMMUNOGLOBULIN G; INTERLEUKIN 6; MESSENGER RNA; TOLL LIKE RECEPTOR 4; BLEOMYCIN; CYTOKINE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; BLEOMYCIN INDUCED FIBROSIS; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; FIBROSIS; FLOW CYTOMETRY; GENE DELETION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INDEL MUTATION; INFLAMMATORY CELL; KNOCKOUT GENE; LUNG FIBROSIS; MOUSE; NONHUMAN; POLARIZATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKIN DEFECT; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH17 CELL; TH2 CELL; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN;

ANIMALS; BLEOMYCIN; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TOLL-LIKE RECEPTOR 4;

EID: 84919919841     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38901     Document Type: Article

References (50)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
3. Sato S, Hasegawa M, Takehara K,. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-6.
4. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K,. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 328-32.
5. Hasegawa M, Sato S, Takehara K,. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999; 117: 159-65.
6. Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, et al. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 2008; 35: 120-5.
7. Yamamoto T, Nishioka K,. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003; 121: 510-6.
8. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007; 104: 2827-30.
9. Sakkas LI, Chikanza IC, Platsoucas CD,. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 679-85.
10. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S,. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-84.
11. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165-76.
12. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010; 49: 2408-12.
13. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Le Huu D, Iwakura Y, et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 2012; 64: 3726-35.
14. Lafyatis R, York M,. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009; 21: 617-22.
15. Akira S,. Toll-like receptor signaling. J Biol Chem 2003; 278: 38105-8.
16. Liew FY, Xu D, Brint EK, O'Neill LA,. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446-58.
17. Iwasaki A, Medzhitov R,. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
18. Marshak-Rothstein A,. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-35.
19. Janeway CA Jr, Medzhitov R,. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
20. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009; 29: 180-9.
21. Yoshizaki A, Iwata Y, Komura K, Hara T, Ogawa F, Muroi E, et al. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol 2008; 35: 1825-9.
22. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013; 182: 192-205.
23. McElwee KJ, Hoffmann R,. Alopecia areata: animal models. Clin Exp Dermatol 2002; 27: 410-7.
24. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
25. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
26. Gallucci RM, Sloan DK, Heck JM, Murray AR, O'Dell SJ,. Interleukin 6 indirectly induces keratinocyte migration. J Invest Dermatol 2004; 122: 764-72.
27. Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron L, Sapino A, et al. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res 2006; 4: 351-9.
28. Zeini M, Traves PG, Lopez-Fontal R, Pantoja C, Matheu A, Serrano M, et al. Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis. J Immunol 2006; 177: 3327-36.
29. Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012; 71: 1235-42.
30. Green MC, Sweet HO, Bunker LE,. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493-512.
31. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
32. Liu B, Yang Y, Dai J, Medzhitov R, Freudenberg MA, Zhang PL, et al. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006; 177: 6880-8.
33. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011; 208: 1459-71.
34. Kraaij MD, van Laar JM,. The role of B cells in systemic sclerosis. Biologics 2008; 2: 389-95.
35. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
36. Ishikawa O, Ishikawa H,. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992; 19: 1202-6.
37. Yamamoto T, Katayama I,. Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol 2011; 2011: 270938.
38. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014. E-pub ahead of print.
39. Akira S, Hirano T, Taga T, Kishimoto T,. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990; 4: 2860-7.
40. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA,. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997; 185: 461-9.
41. Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H, Andersson R,. TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med 2011; 9: 219.
42. O'Reilly S, Hugle T, van Laar JM,. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 2012; 51: 1540-9.
43. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-β independent. J Immunol 2004; 173: 4020-9.
44. Korn T, Bettelli E, Oukka M, Kuchroo VK,. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
45. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008; 29: 628-36.
46. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010; 207: 535-52.
47. Jimenez SA, Williams CJ, Myers JC, Bashey RI,. Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem 1986; 261: 657-62.
48. Zhu H, Bona C, McGaha TL,. Polymorphisms of the TGF-β1 promoter in tight skin (TSK) mice. Autoimmunity 2004; 37: 51-5.
49. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
50. Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA,. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-β production by fibroblasts. Proc Natl Acad Sci U S A 2002; 99: 3800-5.